CVC Capital Partners’s $703 Million Acquisition of Theramex

Latham & Watkins advised CVC Capital Partners on CVC Fund VI’s acquisition of Teva Pharmaceutical Industries Ltd’s international women’s health assets.

The new company, called Theramex, is a global specialty pharmaceutical company dedicated to women and their health. Headquartered in London, UK, the company will market a broad range of innovative, branded and branded generic products across 50 countries around the world. The portfolio, which is dedicated to women’s health, focuses on contraception, fertility, menopause and osteoporosis.

Latham & Watkins has advised CVC on the deal with a London team led by corporate partner Robbie McLaren (picture), assisted by associates Karima Salway, Emily Cridland, Samantha Peacock, Ei Nge Htut and Andria Varnavides. Advice was also provided on IP matters by partner Gail Crawford with associate Rachael Hammond; on separation and supply matters by associates Frances Stocks Allen and Terese Saplys; on regulatory matters by counsel Elizabeth Richards and associate Eitan Bernstein; and on employment matters by associate Shaun Thompson.

Involved fees earner: Robbie McLaren – Latham & Watkins; Karima Salway – Latham & Watkins; Emily Cridland – Latham & Watkins; Samantha Peacock – Latham & Watkins; Ei Nge Htut – Latham & Watkins; Andria Varnavides – Latham & Watkins; Gail Crawford – Latham & Watkins; Rachael Hammond – Latham & Watkins; Terese Saplys – Latham & Watkins; Frances Stocks – Latham & Watkins; Shaun Thompson – Latham & Watkins; Elizabeth Richards – Latham & Watkins; Eitan Bernstein – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: CVC Capital Partners;

Print Friendly, PDF & Email